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KIMBERLY JAMIE* 
Introduction 
Pharmacogenetics, often referred to as ‘personalised’ or 
‘stratified’ medicine, is concerned with genetically-
determined drug response variability. It is personalised in the 
sense that it represents a departure from traditional ‘one size 
fits all’ prescribing models by utilising patients’ genetic 
information to arrive at a more tailored treatment regime 
through the adjustment of drug choices and dosages 
accordingly. In doing so, pharmacogenetics is widely extolled 
as a way of reducing the burden that adverse drug reactions 
(ADRs) place on health care systems, namely the UK 
National Health Service (NHS), and improving the experience 
and management of ‘non-responder’ patients. In the UK, 
ADRs are estimated to cost the NHS around £2 billion 
annually (Compass, 2008) and have been identified as the 
fourth leading cause of death in the United States of America 
(USA) (Lazarou et al., 1998). In addition, in the year 2003 the 
extent of patient non-responsiveness to medications was 
highlighted when Allen Roses (the then worldwide vice-
president of genetics at GlaxoSmithKline) claimed that 
around 90% of drugs only work in 30-50% of patients 
(Connor, 2003). Hence, by introducing genetic factors into the 
drug production and prescribing processes, it has been argued 
that pharmacogenetics will make a ‘major impact in 
commercial labs and in the clinic’ (Webster et al., 2004).  
Pharmacogenetics has been posited as the ‘next great 
challenge’ for pharmacy practice (Clemerson et al., 2006) as 
pharmacists will have an ‘essential role to play’ (Akhtar, 
2002: 299) in delivering pharmacogenetic medicine in the 
hospital and community in the future. The exact nature of this 
role, particularly in community pharmacy, is, however, yet to 
be established as pharmacogenetics has made limited impact 
outside of tertiary or secondary care settings. Even so, roles 
around testing, results interpretation, counselling patients and 
offering advice to other healthcare practitioners have 
previously been suggested for pharmacists (Clemerson et al., 
2006). Within these discussions of potential future roles for 
pharmacists, a focus on genetic education has been 
forgrounded. This discursive focus on pharmacists’ genetic 
educational needs has also been centralised in health policy.  
In 2003 the genetics advisory group to the UK government, 
the Human Genetics Commission, highlighted the need for a 
‘genetically literate’ primary care workforce to manage 
patient access to appropriate genetic testing (Human Genetics 
Commission, 2003). In the same year, Burton and 
Shuttleworth (2003) noted that although British 
undergraduate pharmacists were in receipt of scientific 
training around genetics, their education in legal, ethical and 
social implications of genetic medicine was insufficient. 
Moreover, they argued that training in the principles of 
genetics was not a priority during preregistration or 
professional development. Following recommendations from 
the UK Department of Health’s White Paper Our Inheritance, 
Our Future (2003), the National Genetics Education and 
Development Centre (NGEDC) was established in 2004 with 
a specialist dedication to pharmacy education in British 
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universities. In 2007 this centre, in collaboration with the 
Royal Pharmaceutical Society (previously the Royal 
Pharmaceutical Society of Great Britain until re-structuring in 
2010) published a report which highlighted the need for 
increased pharmacogenetic education for undergraduate, 
preregistration and more experienced pharmacists (Newton et 
al., 2007). 
In the USA, the integration of pharmacogenetics into 
pharmacy curricula has also been identified as a priority. In 
their study of the nature of pharmacogenetic teaching in 
American colleges and schools of pharmacy, for example, 
Lafit and McKay (2005) found that 78% of the institutions 
surveyed provided some instruction on pharmacogenetics. 
More recently, Murphy et al. (2010) revisited Latif and 
McKay’s work and found that the proportion of institutions 
teaching pharmacogenetics had increased to 92%. Despite 
this increase, Murphy et al. (2010) found that the ‘depth’ of 
pharmacogenetic teaching was  still limited with only two of 
nine competencies in the ethical applications and economic 
implications of pharmacogenetics being taught in at least 50% 
of colleges.  
Despite the potential for pharmacogenetics to make a 
significant impact on pharmacy practice and the recent policy 
focus on pharmacists’ genetic education in the UK and 
elsewhere, relatively little research has been undertaken to 
assess British pharmacists’ familiarity with genetics. Given 
this, this paper draws on empirical interview data to explore 
the educational challenges around implementing 
pharmacogenetics into pharmacy education.   
 
Methods 
The author undertook qualitative research to elicit the 
perspectives of stakeholders and practitioners as to the 
potential futures of pharmacogenetics in hospital and 
community pharmacy. In total, thirty eight respondents were 
interviewed using semi-structured topic guides. Each of the 
interviews (of which three were group interviews) lasted 
between thirty and sixty minutes and were digitally recorded 
and later transcribed. Where necessary, telephone interviews 
were also offered and undertaken. 
Respondents were drawn from a number of fields associated 
with pharmacogenetic technology and pharmacy practice in 
order to produce a detailed overview of the complexities of 
implementing pharmacogenetics into pharmacy. This 
sampling technique allowed the perspectives of those 
developing pharmacogenetic technologies, those currently 
engaging in pharmacogenetic practices and those who will 
potentially practise in this way in future to be encompassed.  
Respondents were, then, drawn from five key (although not 
mutually exclusive and not reflective of respondents’ wider 
skills or interests) fields. These practice fields were 
pharmacogenetic science , oncology , pharmacy policy and 
representation (what are being called here ‘pharmacy 
stakeholders’), general medical practice and hospital and 
community pharmacy. Pharmacogenetic scientists, 
oncologists and pharmacy stakeholders were identified using 
internet searches of relevant bodies and practitioners. These 
potential respondents were then contacted by e-mail with a 
request to participate in an interview about pharmacogenetics 
and pharmacy practice. This method of recruitment proved 
effective with 14 interviews being arranged following 14 
initial e-mails.  In a number of instances, the initial e-mail was 
forwarded to people or groups who were more appropriate 
given the topic of the research. Hence, these 14 interviews 
stemming from 14 recruitment e-mails does not represent a 
100% response rate although it nonetheless demonstrates the 
effectiveness of this sampling strategy. 
General practitioners and pharmacists were less easily 
accessible due to a comparatively limited online presence. In 
the case of general practitioners, a letter drop was sent to 21 
GPs at four surgeries in one English city, which was selected 
for convenience purposes. From this, three respondents agreed 
to participate, although one of these later was unavailable. In 
the case of hospital pharmacists, chief pharmacists at three 
English hospitals were contacted using details that were 
available online. Two of these chief pharmacists were 
interviewed and then acted as gatekeepers to facilitate 
interviews with other hospital pharmacists in their institutions. 
Such informal gatekeeper techniques were also used in 
accessing community pharmacists as a city-wide community 
pharmacy letter drop to 15 pharmacies only elicited one 
respondent. Local Practice Forums and Pharmacy 
Superintendents were also approached as gatekeepers for 
community pharmacy but this contact elicited no responses. 
As such, and given time constraints, informal networks and 
gatekeepers were identified as the most effective recruitment 
technique for community pharmacists. 
The project gained NHS ethics approval from South 
Yorkshire Research Ethics Committee and governance 
approvals from those NHS Trusts from which staff acted as 
respondents. In line with this, and the Helsinki Declaration 
(1975, revised 1983), written informed consent was obtained 
from respondents prior to the interview and all responses were 
anonymised prior to publication.    
The transcribed interview data were analysed using the 
qualitative data analysis software Atlas Ti (version 6). This 
software allowed for a two-fold approach to data analysis 
through the creation of multiple hermeneutic units (projects). 
In one of these units, an inductive (i.e. bottom-up) approach 
was taken to analyse the overarching issues emerging from 
the data. A secondary analysis allowed these overarching 
issues to be sociologically deconstructed using, for example, 
Foucauldian and ‘normalisation’ (May & Finch, 2009) 
frameworks. This paper’s focus on pharmacy education 
represents findings from an initial analysis of the data.  
 
Results 
Through an initial inductive analysis of the interview data, a 
number of themes emerged which focused on the potential 
futures of pharmacogenetics in pharmacy and the challenges 
that it presents. One of these key themes which was discussed 
by 34 respondents across the sample was the issue of 
pharmacists’ education (or lack thereof) in genetic principles, 
which was represented as a challenge to the successful 
integration of pharmacogenetics into pharmacy practice, 
particularly in the community setting. Within this, the notion 
of a generational knowledge gap was salient where an 
increased prominence of genetics in current pharmacy 
education was contrasted with more experienced pharmacists’ 
lack of familiarity with genetic science.  
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This lack of familiarity in pharmacists who have been trained 
for some years was attributed to three main, and inter-related, 
elements. Firstly, in community pharmacy especially, heavy 
workloads mean that pharmacists felt they lacked the time 
needed to familiarise themselves with the latest scientific 
developments that do not directly affect their present practice. 
Secondly, increasing trained pharmacists’ knowledge of 
genetics was thought to be a relatively low priority for 
pharmacy representative bodies. Thirdly, this lack of 
prioritisation of genetics by pharmacy bodies is thought to 
translate into a lack of professional development provision for 
pharmacists who have been qualified for a number of years. 
 
Discussion 
Since the time of the 2003 UK Department of Health report, 
pharmacogenetics has become a more prominent feature of 
undergraduate pharmacy education in the UK with 
opportunities to introduce its principles through a number of 
areas within the General Pharmaceutical Council’s indicative 
accreditation syllabus. Although the extent to which newly 
qualified pharmacists would feel comfortable using 
pharmacogenetics in their routine practice remains under-
researched, the increased presence of pharmacogenetics in 
pharmacy curricula hints at the growth of a relatively 
‘genetically literate’ generation of pharmacists as per the 
Human Genetic Commission’s (2003) recommendations.  
This increased genetic literacy is especially true for junior 
hospital pharmacists whose preregistration training might 
expose them to practices and practitioners where pre-
prescription pharmacogenetic testing is routine given the high 
toxicity of many medications. In the community setting, given 
the comparatively low toxicity of medications and the limited 
financial problems associated with ‘trial and error’ 
prescribing, genetic literacy is more difficult to cultivate as 
pharmacogenetics has a limited presence. Hence, one 
community pharmacist commented “I may be aware of friends 
who have mentioned that [pharmacogenetics] in hospital 
settings, particularly oncology departments and wards, etc., 
but not in the community setting”. This quote highlights that 
pharmacogenetic technologies and practices are, at present, 
more a part of everyday hospital, rather than community, 
pharmacy practice. Hence, the extent to which community 
pharmacists are able to become genetically literate is limited.   
This difference between hospital and community pharmacists’ 
genetic literacy is centred on their everyday work activities 
and the lack of genetics in that of the latter. This is despite the 
increased prominence of genetics in the common university 
curricula where the genetic principles of disease and treatment 
are spread across teaching within the degree. This is 
demonstrated by one junior hospital pharmacist who has been 
registered for around 12 months who commented “it 
[pharmacogenetics] was involved in the modules and you 
were given reading to do around the subject area and then 
you had lectures on it”. This junior pharmacists’ quote 
highlights the increased centrality of pharmacogenetics in 
pharmacy education as genetics increasingly underpins 
medical practice and therapy decisions. This increased 
prominence of genetics in current pharmacy education is in 
contrast to pharmacy education historically where genetics 
had a limited presence on university curricula as one 
community pharmacist commented: “It’s eight years ago… I 
don’t remember having many lectures on pharmacogenomics, 
hardly any in fact”.  
As pre-prescription genetic testing becomes cheaper, the 
importance of genetic information in medical treatment is 
likely to increase further as more medical knowledge and 
decisions become based around genetic information. Given 
this, the prominence of genetic education for all health care 
practitioners, including pharmacists, is likely to increase. 
Through this, the newly trained health care workforce will 
become increasingly genetically literate as per Human 
Genetics Commission (2003) report.  
In contrast to this increased presence of pharmacogenetics in 
current university curricula, the prominence of 
pharmacogenetics in pharmacists’ professional development 
has been limited. In their 2007 report for the NGEDC and the 
RPSGB, Newton et al. (2007) noted that pharmacogenetics 
would need to be ‘demystified’ and proven to be of clinical 
value in order to engage pharmacists who are already 
practising. The interviews undertaken by the current author 
with hospital and community pharmacists suggest that such 
demystification has not occurred as most generalist 
pharmacists who have been practising for more than five to 
ten years are relatively unaware of pharmacogenetic 
principles or developments, as a community pharmacist who 
has been registered for around 30 years highlighted; “my 
generation of pharmacists are probably not very familiar at 
all [with pharmacogenetics]”. This notion of a generational 
knowledge gap vis-à-vis genetics is compounded by a 
pharmacogeneticist who qualified as a pharmacist around 50 
years ago who commented “there’s a whole two generations 
of pharmacists who haven’t had much exposure…it’s an 
educational generational thing”.  
This generational lack of knowledge about genetics was 
attributed to three elements - (i) heavy workloads and a lack 
of time to develop knowledge of new areas; (ii) genetics 
being a low priority for pharmacy representative bodies; and 
(iii) a lack of professional development provision in the area 
of genetics for pharmacists who have been qualified for some 
years. Pharmacy professional bodies’ low prioritisation of 
genetics was thought to place an increased responsibility on 
pharmacists to undertake their own professional development 
in the area of pharmacogenetics. As one hospital pharmacist 
commented, “there’s a responsibility on the part of 
pharmacists to actively go out and learn about things”, 
which is challenging given the heavy workload which 
prevents pharmacists from engaging with developments that 
do not impact on their immediate practice.   
The generational disparity in levels of knowledge about 
pharmacogenetic medicine outlined above presents two main 
challenges. Firstly, as genetic testing becomes cheaper and 
quicker and increasingly available in primary care settings, 
and as media discourse around ‘personalised’ medicine 
becomes more promissory, it is likely that patients will 
engage with and have questions about pharmacogenetic 
medicine. In a research report on patient and practitioners’ 
perspectives of pharmacogenetics in the NHS, Fargher et al. 
(2007) note that health care professionals’ lack of knowledge 
of pharmacogenetics could lead to a gap between ‘patients’ 
high expectations for information’ and the information that 
health care practitioners can actually provide. If pharmacists, 
particularly in the community, are placed in a position to 
offer such pharmacogenetic information (see Clemerson et 
al., 2006), there is a risk that patients may receive different 
advice depending on their particular pharmacist and the 
length of time that he/she has been practising.  
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Secondly, it has been highlighted elsewhere that pharmacists 
are in a pivotal position to secure a prominent role in 
delivering pharmacogenetic medicine, which could be 
beneficial for patients’ experiences of genetic health care and 
increasing the professional profile of pharmacy (Clemerson et 
al., 2006; Maitland-van der Zee et al., 2004; Streetman, 
2007). In order to legitimately stake claims for such 
involvement, the pharmacy profession will need to 
demonstrate that all of its members are suitably trained in this 
new paradigm of practice. If the generational knowledge gap 
persists whilst pharmacogenetic medicine is being 
implemented into routine clinical practice, there is a risk that 
pharmacists may be overlooked for central involvement in 
delivering pharmacogenetic medicine. It is, thus, imperative 
that the Royal Pharmaceutical Society and other 
representative bodies engage with the debates and challenges 
presented by pharmacogenetics in routine pharmacy practice 
and seek to bridge the generational gap through initiatives 
such as incorporating pharmacogenetic principles into clinical 
diploma curricula, running pharmacogenetics-focused 
workshops or implementing national training initiatives.  
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